Picture of 4Sc AG logo

VSC 4Sc AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+0.51%
3m-9.48%
6m-18.81%
1yr+140.33%
Volume Change (%)
10d/3m-63.13%
Price vs... (%)
52w High-50.5%
50d MA+3.13%
200d MA-0.23%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value17.94
Price to Tang. Book20.51
Price to Free Cashflown/a
Price to Sales298.1
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-146.7%
Return on Equity-89.82%
Operating Margin-2756.91%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of 4Sc AG EPS forecast chart

Profile Summary

4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
August 30th, 2000
Public Since
February 25th, 2008
No. of Employees
15
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
de flag iconFrankfurt Stock Exchange
Shares in Issue
10,114,009

VSC Share Price Performance

Upcoming Events for VSC

4Sc AG Annual Shareholders Meeting

4Sc AG Annual Shareholders Meeting

Q2 2024 4Sc AG Earnings Release

Q3 2024 4Sc AG Earnings Release

Similar to VSC

Picture of CureVac NV logo

CureVac NV

de flag iconFrankfurt Stock Exchange

Picture of Diagonal Bio AB logo

Diagonal Bio AB

de flag iconFrankfurt Stock Exchange

Picture of Medpace Holdings logo

Medpace Holdings

de flag iconFrankfurt Stock Exchange

Picture of PAION AG logo

PAION AG

de flag iconFrankfurt Stock Exchange

Picture of Qiagen NV logo

Qiagen NV

de flag iconFrankfurt Stock Exchange

FAQ